PHASE I DOSE ESCALATING STUDY OF RECOMBINANT HUMAN INTERLEUKIN 12

重组人白细胞介素 12 的 I 期剂量递增研究

• 批准号: 3740349
• 负责人: MICHAEL B ATKINS
• 金额: --
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3740349
• 关键词: antineoplastics; clinical trials; dosage; drug administration routes; human subject; human therapy evaluation; immunopharmacology; natural killer cells; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; recombinant proteins

A Phase I study of recombinant human IL-12 in patients with advanced malignancies. The end points are assessments of dosing against toxicity, pharmacology immunologic effects, and possible suppression of tumor growth. The study will be conducted at 4 centers with a maximum of 42 patients with 10-15 from NEMC anticipated. IL-12 naturally occurring cytokine which has been shown to have multiple effects in vitro including to enhance NK cell activity, to stimulate proliferation of T lymphocytes and NK cells.

重组人IL-12在晚期乳腺癌患者中的I期研究 恶性肿瘤 终点是针对毒性的剂量评估， 药理学、免疫学效应和可能的肿瘤抑制 增长 本研究将在4家临床试验机构进行，最多42例 预计NEMC的患者为10-15例。 IL-12天然存在 细胞因子在体外显示出多种作用，包括 增强NK细胞活性，刺激T淋巴细胞增殖 和NK细胞。